Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non–small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic predictors of therapeutic response to clinically relevant compounds. Using this approach, we showed that v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations confer enhanced Hsp90 dependency and validated this finding in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor. In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice. Thus, genomically annotated cell-line collections may help translate cancer genomics information into clinical practice by defining critical pathway dependencies amenable to therapeutic inhibition.
Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Ullrich, Mirjam Koker, Florian Fischer, Takeshi Shimamura, Daniel Rauh, Craig Mermel, Stefanie Fischer, Isabel Stückrath, Stefanie Heynck, Rameen Beroukhim, William Lin, Wendy Winckler, Kinjal Shah, Thomas LaFramboise, Whei F. Moriarty, Megan Hanna, Laura Tolosi, Jörg Rahnenführer, Roel Verhaak, Derek Chiang, Gad Getz, Martin Hellmich, Jürgen Wolf, Luc Girard, Michael Peyton, Barbara A. Weir, Tzu-Hsiu Chen, Heidi Greulich, Jordi Barretina, Geoffrey I. Shapiro, Levi A. Garraway, Adi F. Gazdar, John D. Minna, Matthew Meyerson, Kwok-Kin Wong, Roman K. Thomas
Title and authors | Publication | Year |
---|---|---|
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, Jagannath S, Parekh S, Sperling AS, Rosenbaum CA, Munshi N, Luskin MR, Tamrazi A, Reid CA |
JCO Precision Oncology | 2024 |
Progress in patient-derived liver cancer cell models: a step forward for precision medicine.
Zhang Z, Hui L |
Acta Biochimica et Biophysica Sinica | 2023 |
Patient-Derived In Vitro and In Vivo Models of Cancer.
Claridge SE, Cavallo JA, Hopkins BD |
Advances in experimental medicine and biology | 2022 |
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
Spagnuolo A, Maione P, Gridelli C |
Translational Lung Cancer Research | 2022 |
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
Psilopatis I, Karniadakis I, Danos KS, Vrettou K, Michaelidou K, Mavridis K, Agelaki S, Theocharis S |
International journal of molecular sciences | 2022 |
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
F He, Y Matsumoto, Y Asano, Y Yamamura, T Katsuyama, JL Rose, N Tomonobu, NL Komalasari, M Sakaguchi, R Rottapel, J Wada |
Frontiers in Oncology | 2021 |
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
M Xie, X Xu, Y Fan |
Frontiers in Oncology | 2021 |
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
JH Luttman, A Colemon, B Mayro, AM Pendergast |
Cell Communication and Signaling | 2021 |
Measurement and models accounting for cell death capture hidden variation in compound response
SY Bae, N Guan, R Yan, K Warner, SD Taylor, AS Meyer |
Cell Death and Disease | 2020 |
Steroid receptor‐associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies
A Naderi |
EMBO reports | 2020 |
Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
JF Creeden, K Alganem, AS Imami, ND Henkel, FC Brunicardi, SH Liu, R Shukla, T Tomar, F Naji, RE McCullumsmith |
International journal of molecular sciences | 2020 |
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
EJ Mucaki, JZ Zhao, DJ Lizotte, PK Rogan |
Signal Transduction and Targeted Therapy | 2019 |
mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial–mesenchymal transition
Y Chen, W LI, P Peng, W Zhao, Y Tian, Y Huang, S Xia, Y Chen |
Acta Pharmacologica Sinica | 2019 |
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
BC Creelan, JE Gray, T Tanvetyanon, AA Chiappori, T Yoshida, MJ Schell, SJ Antonia, EB Haura |
British Journal of Cancer | 2019 |
An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines
J Dutil, Z Chen, AN Monteiro, JK Teer, SA Eschrich |
Cancer research | 2019 |
Xenograft and organoid model systems in cancer research
M Bleijs, M Wetering, H Clevers, J Drost |
The EMBO Journal | 2019 |
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
NE Berlow, R Rikhi, M Geltzeiler, J Abraham, MN Svalina, LE Davis, E Wise, M Mancini, J Noujaim, A Mansoor, MJ Quist, KL Matlock, MW Goros, BS Hernandez, YC Doung, K Thway, T Tsukahara, J Nishio, ET Huang, S Airhart, CJ Bult, R Gandour-Edwards, RG Maki, RL Jones, JE Michalek, M Milovancev, S Ghosh, R Pal, C Keller |
BMC Cancer | 2019 |
A Pharmacogenomic Landscape in Human Liver Cancers
Z Qiu, H Li, Z Zhang, Z Zhu, S He, X Wang, P Wang, J Qin, L Zhuang, W Wang, F Xie, Y Gu, K Zou, C Li, C Li, C Wang, J Cen, X Chen, Y Shu, Z Zhang, L Sun, L Min, Y Fu, X Huang, H Lv, H Zhou, Y Ji, Z Zhang, Z Meng, X Shi, H Zhang, Y Li, L Hui |
Cancer Cell | 2019 |
A combined tissue-engineered/ in silico signature tool patient stratification in lung cancer
C Göttlich, M Kunz, C Zapp, SL Nietzer, H Walles, T Dandekar, G Dandekar |
Molecular Oncology | 2018 |
Mutations, protein homeostasis, and epigenetic control of genome integrity
JL Xie, DF Jarosz |
DNA repair | 2018 |
Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy
XM Qi, F Wang, M Mortensen, R Wertz, G Chen |
Acta pharmaceutica Sinica. B | 2018 |
YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
FL Sardo, S Strano, G Blandino |
Cancers | 2018 |
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
DS Subramaniam, SV Liu, J Crawford, J Kramer, J Thompson, H Wang, G Giaccone |
Frontiers in Oncology | 2018 |
Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer
J Gordon, M Brown, M Reynolds |
Diseases | 2018 |
Methods, Tools and Current Perspectives in Proteogenomics
KV Ruggles, K Krug, X Wang, KR Clauser, J Wang, SH Payne, D Fenyö, B Zhang, DR Mani |
Molecular & cellular proteomics : MCP | 2017 |
Mechanoresponsive stem cells to target cancer metastases through biophysical cues
L Liu, SX Zhang, W Liao, HP Farhoodi, CW Wong, CC Chen, AI Ségaliny, JV Chacko, LP Nguyen, M Lu, G Polovin, EJ Pone, TL Downing, DA Lawson, MA Digman, W Zhao |
Science Translational Medicine | 2017 |
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
J Brägelmann, MA Dammert, F Dietlein, JM Heuckmann, A Choidas, S Böhm, A Richters, D Basu, V Tischler, C Lorenz, P Habenberger, Z Fang, S Ortiz-Cuaran, F Leenders, J Eickhoff, U Koch, M Getlik, M Termathe, M Sallouh, Z Greff, Z Varga, H Balke-Want, CA French, M Peifer, HC Reinhardt, L Örfi, G Kéri, S Ansén, LC Heukamp, R Büttner, D Rauh, BM Klebl, RK Thomas, ML Sos |
Cell Reports | 2017 |
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
D Plenker, M Riedel, J Brägelmann, MA Dammert, R Chauhan, PP Knowles, C Lorenz, M Keul, M Bührmann, O Pagel, V Tischler, AH Scheel, D Schütte, Y Song, J Stark, F Mrugalla, Y Alber, A Richters, J Engel, F Leenders, JM Heuckmann, J Wolf, J Diebold, G Pall, M Peifer, M Aerts, K Gevaert, RP Zahedi, R Buettner, KM Shokat, NQ McDonald, SM Kast, O Gautschi, RK Thomas, ML Sos |
Science Translational Medicine | 2017 |
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
B Gaschler-Markefski, P Sikken, JV Heymach, M Gottfried, A Mellemgaard, S Novello, CN Gann, J Barrueco, M Reck, NH Hanna, R Kaiser |
ESMO Open | 2017 |
Ex vivo tumor culture systems for functional drug testing and therapy response prediction
TG Meijer, KA Naipal, A Jager, DC van Gent |
Future Science OA | 2017 |
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
CM Parseghian, NU Parikh, JY Wu, ZQ Jiang, L Henderson, F Tian, B Pastor, M Ychou, K Raghav, A Dasari, DR Fogelman, AD Katsiampoura, DG Menter, RA Wolff, C Eng, MJ Overman, AR Thierry, GE Gallick, S Kopetz |
Clinical cancer research | 2017 |
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
A Rouhi, C Miller, S Grasedieck, S Reinhart, B Stolze, H Döhner, F Kuchenbauer, L Bullinger, S Fröhling, C Scholl |
Oncotarget | 2017 |
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
MD Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, MD Maio, I Petrini, R Danesi |
Oncotarget | 2017 |
Sequential feature selection and inference using multi-variate random forests
J Mayer, R Rahman, S Ghosh, R Pal, J Kelso |
Bioinformatics | 2017 |
Inactivation of ABL kinases Suppresses Non-Small-Cell Lung Cancer Metastasis
Jing Jin Gu, Clay Rouse, Xia Xu, Jun Wang, Mark Onaitis, Ann Marie Pendergast |
JCI Insight | 2016 |
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
P Tomasini, P Walia, C Labbe, K Jao, NB Leighl |
The oncologist | 2016 |
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging
D Fecher, E Hofmann, A Buck, R Bundschuh, S Nietzer, G Dandekar, T Walles, H Walles, K Lückerath, M Steinke, N Cordes |
PloS one | 2016 |
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines
C Yu, AM Mannan, GM Yvone, KN Ross, YL Zhang, MA Marton, BR Taylor, A Crenshaw, JZ Gould, P Tamayo, BA Weir, A Tsherniak, B Wong, LA Garraway, AF Shamji, MA Palmer, MA Foley, W Winckler, SL Schreiber, AL Kung, TR Golub |
Nature Biotechnology | 2016 |
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response
ML Nickerson, N Witte, KM Im, S Turan, C Owens, K Misner, SX Tsang, Z Cai, S Wu, M Dean, JC Costello, D Theodorescu |
Oncogene | 2016 |
The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis
FJ Xie, HY Lu, QQ Zheng, J Qin, Y Gao, YP Zhang, X Hu, WM Mao |
OncoTargets and therapy | 2016 |
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
YJ Kim, S Hong, M Sung, MJ Park, K Jung, KW Noh, DY Oh, MS Lee, E Oh, YK Shin, YL Choi |
Oncotarget | 2016 |
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer: Kras driven expression signature in NSCLC
Á Nagy, LS Pongor, A Szabó, M Santarpia, B Győrffy |
International Journal of Cancer | 2016 |
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
MM Stevens, CL Maire, N Chou, MA Murakami, DS Knoff, Y Kikuchi, RJ Kimmerling, H Liu, S Haidar, NL Calistri, N Cermak, S Olcum, NA Cordero, A Idbaih, PY Wen, DM Weinstock, KL Ligon, SR Manalis |
Nature Biotechnology | 2016 |
The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine: Cell line panel for veterinary oncology
JS Fowles, DD Dailey, DL Gustafson, DH Thamm, DL Duval |
Veterinary and Comparative Oncology | 2016 |
Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery
CM Johannessen, PA Clemons, BK Wagner |
Trends in Genetics | 2015 |
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor
N Ishida, T Fukazawa, Y Maeda, T Yamatsuji, M Takaoka, M Haisa, E Yokota, K Shigemitsu, I Morita, K Kato, K Matsumoto, T Shimo, T Okui, XH Bao, H Hao, SN Grant, N Takigawa, JA Whitsett, Y Naomoto |
Experimental Cell Research | 2015 |
Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers
L Dodbiba, J Teichman, A Fleet, H Thai, MH Starmans, R Navab, Z Chen, H Girgis, L Eng, O Espin-Garcia, X Shen, B Bandarchi, J Schwock, MS Tsao, H El-Zimaity, SD Der, W Xu, RG Bristow, GE Darling, PC Boutros, LE Ailles, G Liu, WA Phillips |
PloS one | 2015 |
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
HS Kim, YJ Sung, S Paik |
Yonsei Medical Journal | 2015 |
The Emerging Role of ABL Kinases in Solid Tumors
J Wang, AM Pendergast |
Trends in Cancer | 2015 |
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
MB Schabath, EA Welsh, WJ Fulp, L Chen, JK Teer, ZJ Thompson, BE Engel, M Xie, AE Berglund, BC Creelan, SJ Antonia, JE Gray, SA Eschrich, DT Chen, WD Cress, EB Haura, AA Beg |
Oncogene | 2015 |
Pharmacogenomic agreement between two cancer cell line data sets
N Stransky, M Ghandi, GV Kryukov, LA Garraway, J Lehár, M Liu, D Sonkin, A Kauffmann, K Venkatesan, EJ Edelman, M Riester, J Barretina, G Caponigro, R Schlegel, WR Sellers, F Stegmeier, M Morrissey, A Amzallag, I Pruteanu-Malinici, DA Haber, S Ramaswamy, CH Benes, MP Menden, F Iorio, MR Stratton, U McDermott, MJ Garnett, J Saez-Rodriguez |
Nature | 2015 |
A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction
S Haider, R Rahman, S Ghosh, R Pal, A Gursoy |
PloS one | 2015 |
Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity
LC Li, TY Wong |
Journal of proteomics & bioinformatics | 2015 |
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells
PJ Webber, C Park, M Qui, SS Ramalingam, FR Khuri, H Fu, Y Du |
Oncoscience | 2015 |
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
A Goodspeed, LM Heiser, JW Gray, JC Costello |
Molecular cancer research : MCR | 2015 |
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
M Larrayoz, R Pio, MJ Pajares, I Zudaire, D Ajona, O Casanovas, LM Montuenga, J Agorreta |
EMBO Molecular Medicine | 2014 |
Oncogenic RIT1 mutations in lung adenocarcinoma
AH Berger, M Imielinski, F Duke, J Wala, N Kaplan, GX Shi, DA Andres, M Meyerson |
Oncogene | 2014 |
A Diverse Stochastic Search Algorithm for Combination Therapeutics
MU Caglar, R Pal |
BioMed Research International | 2014 |
Systems biology approaches to develop innovative strategies for lung cancer therapy
K Viktorsson, R Lewensohn, B Zhivotovsky |
Cell Death and Disease | 2014 |
An Ensemble Based Top Performing Approach for NCI-DREAM Drug Sensitivity Prediction Challenge
Q Wan, R Pal |
PloS one | 2014 |
Genetic modifiers of EGFR dependence in non-small cell lung cancer
T Sharifnia, V Rusu, F Piccioni, M Bagul, M Imielinski, AD Cherniack, CS Pedamallu, B Wong, FH Wilson, LA Garraway, D Altshuler, TR Golub, DE Root, A Subramanian, M Meyerson |
Proceedings of the National Academy of Sciences | 2014 |
Association Between the Cytogenetic Profile of Tumor Cells and Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer:
M González-González, J Garcia, JA Alcazar, ML Gutiérrez, LM Gónzalez, O Bengoechea, MM Abad, A Santos-Briz, O Blanco, M Martín, A Rodríguez, M Fuentes, L Muñoz-Bellvis, A Orfao, JM Sayagues |
Medicine | 2014 |
Prediction of individual response to anticancer therapy: historical and future perspectives
FT Unger, I Witte, KA David |
Cellular and Molecular Life Sciences | 2014 |
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers
RP Abo, M Ducar, EP Garcia, AR Thorner, V Rojas-Rudilla, L Lin, LM Sholl, WC Hahn, M Meyerson, NI Lindeman, PV Hummelen, LE MacConaill |
Nucleic Acids Research | 2014 |
Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
H Ebi, AC Faber, JA Engelman, S Yano |
Cancer Science | 2014 |
Inference of dynamic biological networks based on responses to drug perturbations
N Berlow, L Davis, C Keller, R Pal |
EURASIP Journal on Bioinformatics and Systems Biology | 2014 |
Cell-autonomous autocrine VEGF:VEGFR2 feed-forward loop triggers the angiogenic switch in lung cancer
Sampurna Chatterjee, Lukas Heukamp, Maike Siobal, Jakob Schoettle, Caroline Wieczorek, Martin Peifer, Davide Frasca, Mirjam Koker, Katharina Koenig, Lydia Meder, Daniel Rauh, Reinhard Büttner, Juergen Wolf, Rolf Brekken, Bernd Neumaier, Gerhard Christofori, Roman Thomas, Roland Ullrich |
Journal of Clinical Investigation | 2013 |
Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model
AT Stratmann, D Fecher, G Wangorsch, C Göttlich, T Walles, H Walles, T Dandekar, G Dandekar, SL Nietzer |
Molecular Oncology | 2013 |
Molecular dissection of AKT activation in lung cancer cell lines
Y Guo, J Du, DJ Kwiatkowski |
Molecular cancer research : MCR | 2013 |
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412
S Ståhl, VO Kaminskyy, G Efazat, AH Vaculova, S Rodriguez-Nieto, A Moshfegh, R Lewensohn, K Viktorsson, B Zhivotovsky |
Cell Death and Disease | 2013 |
Metrics other than potency reveal systematic variation in responses to cancer drugs
M Fallahi-Sichani, S Honarnejad, LM Heiser, JW Gray, PK Sorger |
Nature Chemical Biology | 2013 |
Targeted therapies in development for non-small cell lung cancer
T Reungwetwattana, GK Dy |
Journal of carcinogenesis | 2013 |
Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma
M Bøgsted, AE Bilgrau, CP Wardell, U Bertsch, A Schmitz, JS Bødker, MK Kjeldsen, H Goldschmidt, GJ Morgan, K Dybkaer, HE Johnsen |
PloS one | 2013 |
Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status
M Planck, K Edlund, J Botling, P Micke, S Isaksson, J Staaf |
PloS one | 2013 |
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data
N Berlow, LE Davis, EL Cantor, B Séguin, C Keller, R Pal |
BMC bioinformatics | 2013 |
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
AY Chang, M Wang |
BMC Cancer | 2013 |
Collections of simultaneously altered genes as biomarkers of cancer cell drug response
DL Masica, R Karchin |
Cancer research | 2013 |
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target
H Watanabe, JM Francis, MS Woo, B Etemad, W Lin, DF Fries, S Peng, EL Snyder, PR Tata, F Izzo, AC Schinzel, J Cho, PS Hammerman, RG Verhaak, WC Hahn, J Rajagopal, T Jacks, M Meyerson |
Genes & development | 2013 |
Role of ABL Family Kinases in Cancer: from Leukemia to Solid Tumors
EK Greuber, P Smith-Pearson, J Wang, AM Pendergast |
Nature Reviews Cancer | 2013 |
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
MA Socinski, J Goldman, I El-Hariry, M Koczywas, V Vukovic, L Horn, E Paschold, R Salgia, H West, LV Sequist, P Bonomi, J Brahmer, LC Chen, A Sandler, CP Belani, T Webb, H Harper, M Huberman, S Ramalingam, KK Wong, F Teofilovici, W Guo, GI Shapiro |
Clinical cancer research | 2013 |
Characteristics of Lung Cancers Harboring NRAS Mutations
K Ohashi, LV Sequist, ME Arcila, CM Lovly, , CM Rudin, T Moran, DR Camidge, CL Vnencak-Jones, L Berry, Y Pan, H Sasaki, JA Engelman, EB Garon, SM Dubinett, WA Franklin, GJ Riely, ML Sos, MG Kris, D Dias-Santagata, M Ladanyi, PA Bunn, W Pao |
Clinical cancer research | 2013 |
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
N Azoitei, CM Hoffmann, JM Ellegast, CR Ball, K Obermayer, U Gossele, B Koch, K Faber, F Genze, M Schrader, HA Kestler, H Dohner, G Chiosis, H Glimm, S Frohling, C Scholl |
Journal of Experimental Medicine | 2012 |
Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer
T Shimamura, SA Perera, KP Foley, J Sang, SJ Rodig, T Inoue, L Chen, D Li, J Carretero, YC Li, P Sinha, CD Carey, CL Borgman, JP Jimenez, M Meyerson, W Ying, J Barsoum, KK Wong, GI Shapiro |
Clinical cancer research | 2012 |
Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer
G Zhuang, W Song, K Amato, Y Hwang, K Lee, M Boothby, F Ye, Y Guo, Y Shyr, L Lin, DP Carbone, DM Brantley-Sieders, J Chen |
JNCI Journal of the National Cancer Institute | 2012 |
Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
A Haupt, G Joberty, M Bantscheff, H Fröhlich, H Stehr, MR Schweiger, A Fischer, M Kerick, ST Boerno, A Dahl, M Lappe, H Lehrach, C Gonzalez, G Drewes, BM Lange |
BMC Cancer | 2012 |
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, CJ Wilson, J Lehár, GV Kryukov, D Sonkin, A Reddy, M Liu, L Murray, MF Berger, JE Monahan, P Morais, J Meltzer, A Korejwa, J Jané-Valbuena, FA Mapa, J Thibault, E Bric-Furlong, P Raman, A Shipway, IH Engels, J Cheng, GK Yu, J Yu, P Aspesi, M Silva, K Jagtap, MD Jones, L Wang, C Hatton, E Palescandolo, S Gupta, S Mahan, C Sougnez, RC Onofrio, T Liefeld, L MacConaill, W Winckler, M Reich, N Li, JP Mesirov, SB Gabriel, G Getz, K Ardlie, V Chan, VE Myer, BL Weber, J Porter, M Warmuth, P Finan, JL Harris, M Meyerson, TR Golub, MP Morrissey, WR Sellers, R Schlegel, LA Garraway |
Nature | 2012 |
Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
B Sen, S Peng, X Tang, HS Erickson, H Galindo, T Mazumdar, DJ Stewart, I Wistuba, FM Johnson |
Science Translational Medicine | 2012 |
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
MD Wilkerson, X Yin, V Walter, N Zhao, CR Cabanski, MC Hayward, CR Miller, MA Socinski, AM Parsons, LB Thorne, BE Haithcock, NK Veeramachaneni, WK Funkhouser, SH Randell, PS Bernard, CM Perou, DN Hayes |
PloS one | 2012 |
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
DA Fennell, C Swanton |
The EPMA Journal | 2012 |
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, D Plenker, F Leenders, R Sun, T Zander, R Menon, M Koker, I Dahmen, C Müller, VD Cerbo, HU Schildhaus, J Altmüller, I Baessmann, C Becker, B Wilde, J Vandesompele, D Böhm, S Ansén, F Gabler, I Wilkening, S Heynck, JM Heuckmann, X Lu, SL Carter, K Cibulskis, S Banerji, G Getz, KS Park, D Rauh, C Grütter, M Fischer, L Pasqualucci, G Wright, Z Wainer, P Russell, I Petersen, Y Chen, E Stoelben, C Ludwig, P Schnabel, H Hoffmann, T Muley, M Brockmann, W Engel-Riedel, LA Muscarella, VM Fazio, H Groen, W Timens, H Sietsma, E Thunnissen, E Smit, DA Heideman, PJ Snijders, F Cappuzzo, C Ligorio, S Damiani, J Field, S Solberg, OT Brustugun, M Lund-Iversen, J Sänger, JH Clement, A Soltermann, H Moch, W Weder, B Solomon, JC Soria, P Validire, B Besse, E Brambilla, C Brambilla, S Lantuejoul, P Lorimier, PM Schneider, M Hallek, W Pao, M Meyerson, J Sage, J Shendure, R Schneider, R Büttner, J Wolf, P Nürnberg, S Perner, LC Heukamp, PK Brindle, S Haas, RK Thomas |
Nature Genetics | 2012 |
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
ML Sos, F Dietlein, M Peifer, J Schottle, H Balke-Want, C Muller, M Koker, A Richters, S Heynck, F Malchers, JM Heuckmann, D Seidel, PA Eyers, RT Ullrich, AP Antonchick, VV Vintonyak, PM Schneider, T Ninomiya, H Waldmann, R Buttner, D Rauh, LC Heukamp, RK Thomas |
Proceedings of the National Academy of Sciences | 2012 |
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition
SJ Smith, M Wilson, JH Ward, CV Rahman, AC Peet, DC Macarthur, FR Rose, RG Grundy, R Rahman |
PloS one | 2012 |
Analysis of gene expression data from non-small cell lung carcinoma cell lines reveals distinct sub-classes from those identified at the phenotype level
AR Dalby, I Emam, R Franke |
PloS one | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
P Saintigny, S Peng, L Zhang, B Sen, II Wistuba, SM Lippman, L Girard, JD Minna, JV Heymach, FM Johnson |
Molecular cancer therapeutics | 2012 |
Phosphosignature predicts dasatinib response in non-small cell lung cancer
M Klammer, M Kaminski, A Zedler, F Oppermann, S Blencke, S Marx, S Müller, A Tebbe, K Godl, C Schaab |
Molecular & cellular proteomics : MCP | 2012 |
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM |
Oncotarget | 2012 |
Drug discovery: Cell lines battle cancer.
Weinstein JN |
Nature | 2012 |
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
RC O'Hagan, J Heyer |
Genes & cancer | 2011 |
MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer
KS Enfield, GL Stewart, LA Pikor, CE Alvarez, S Lam, WL Lam, R Chari |
Journal of Biomedicine and Biotechnology | 2011 |
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
A Dutt, AH Ramos, PS Hammerman, C Mermel, J Cho, T Sharifnia, A Chande, KE Tanaka, N Stransky, H Greulich, NS Gray, M Meyerson |
PloS one | 2011 |
Benchmarking of mutation diagnostics in clinical lung cancer specimens
S Querings, J Altmüller, S Ansén, T Zander, D Seidel, F Gabler, M Peifer, E Markert, K Stemshorn, B Timmermann, B Saal, S Klose, K Ernestus, M Scheffler, W Engel-Riedel, E Stoelben, E Brambilla, J Wolf, P Nürnberg, RK Thomas |
PloS one | 2011 |
Ras, ROS and Proteotoxic Stress: A Delicate Balance
W Xu, J Trepel, L Neckers |
Cancer Cell | 2011 |
miR2Gene: pattern discovery of single gene, multiple genes, and pathways by enrichment analysis of their microRNA regulators
C Qiu, J Wang, Q Cui |
BMC Systems Biology | 2011 |
NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor
T Mori, DD Ikeda, T Fukushima, S Takenoshita, H Kochi |
Cell cycle (Georgetown, Tex.) | 2011 |
Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity
M Rasmussen, M Sundström, HG Kultima, J Botling, P Micke, H Birgisson, B Glimelius, A Isaksson |
Genome biology | 2011 |
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
JM Heuckmann, M Hölzel, ML Sos, S Heynck, H Balke-Want, M Koker, M Peifer, J Weiss, CM Lovly, C Grütter, D Rauh, W Pao, RK Thomas |
Clinical cancer research | 2011 |
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
Z Su, D Dias-Santagata, M Duke, K Hutchinson, YL Lin, DR Borger, CH Chung, PP Massion, CL Vnencak-Jones, AJ Iafrate, W Pao |
The Journal of molecular diagnostics : JMD | 2011 |
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks
M Wang, F Morsbach, D Sander, L Gheorghiu, A Nanda, C Benes, M Kriegs, M Krause, E Dikomey, M Baumann, J Dahm-Daphi, J Settleman, H Willers |
Cancer research | 2011 |
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
HW Cheung, J Du, JS Boehm, F He, BA Weir, X Wang, M Butaney, LV Sequist, B Luo, JA Engelman, DE Root, M Meyerson, TR Golub, PA Jänne, WC Hahn |
Cancer Discovery | 2011 |
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, BA Woods, W Lin, J Zhang, X Deng, SM Lim, S Heynck, M Peifer, JR Simard, MS Lawrence, RC Onofrio, HB Salvesen, D Seidel, T Zander, JM Heuckmann, A Soltermann, H Moch, M Koker, F Leenders, F Gabler, S Querings, S Ansén, E Brambilla, C Brambilla, P Lorimier, OT Brustugun, Å Helland, I Petersen, JH Clement, H Groen, W Timens, H Sietsma, E Stoelben, J Wolf, DG Beer, MS Tsao, M Hanna, C Hatton, MJ Eck, PA Janne, BE Johnson, W Winckler, H Greulich, AJ Bass, J Cho, D Rauh, NS Gray, KK Wong, EB Haura, RK Thomas, M Meyerson |
Cancer Discovery | 2011 |
Integration and analysis of genome-scale data from gliomas
Riddick G, Fine HA |
Nature reviews. Neurology | 2011 |
[Oncology and palliative medicine].
Gärtner J, Wolf J, Voltz R, Hallek M |
Der Internist | 2011 |
Advances in the preclinical testing of cancer therapeutic hypotheses.
Caponigro G, Sellers WR |
Nature reviews. Drug discovery | 2011 |
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, R Menon, S Maier, A Soltermann, H Moch, P Wagener, F Fischer, S Heynck, M Koker, J Schottle, F Leenders, F Gabler, I Dabow, S Querings, LC Heukamp, H Balke-Want, S Ansen, D Rauh, I Baessmann, J Altmuller, Z Wainer, M Conron, G Wright, P Russell, B Solomon, E Brambilla, C Brambilla, P Lorimier, S Sollberg, OT Brustugun, W Engel-Riedel, C Ludwig, I Petersen, J Sanger, J Clement, H Groen, W Timens, H Sietsma, E Thunnissen, E Smit, D Heideman, F Cappuzzo, C Ligorio, S Damiani, M Hallek, R Beroukhim, W Pao, B Klebl, M Baumann, R Buettner, K Ernestus, E Stoelben, J Wolf, P Nurnberg, S Perner, RK Thomas |
Science Translational Medicine | 2010 |
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
M Peifer, J Weiss, ML Sos, M Koker, S Heynck, C Netzer, S Fischer, H Rode, D Rauh, J Rahnenführer, RK Thomas |
PloS one | 2010 |
Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy
U Keller, NV Bubnoff, C Peschel, J Duyster |
Journal of Cellular and Molecular Medicine | 2010 |
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
SV Sharma, DA Haber, J Settleman |
Nature Reviews Cancer | 2010 |
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors
J Voortman, JH Lee, JK Killian, M Suuriniemi, Y Wang, M Lucchi, WI Smith, P Meltzer, Y Wang, G Giaccone |
Proceedings of the National Academy of Sciences | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
EB Haura, T Tanvetyanon, A Chiappori, C Williams, G Simon, S Antonia, J Gray, S Litschauer, L Tetteh, A Neuger, L Song, B Rawal, MJ Schell, G Bepler |
Journal of Clinical Oncology | 2010 |
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
FM Johnson, BN Bekele, L Feng, I Wistuba, XM Tang, HT Tran, JJ Erasmus, LL Hwang, N Takebe, GR Blumenschein, SM Lippman, DJ Stewart |
Journal of Clinical Oncology | 2010 |
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
AF Gazdar, L Girard, WW Lockwood, WL Lam, JD Minna |
JNCI Journal of the National Cancer Institute | 2010 |
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
D Dias-Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, SL Boisvert, H Stubbs, U McDermott, J Settleman, EL Kwak, JW Clark, SJ Isakoff, LV Sequist, JA Engelman, TJ Lynch, DA Haber, DN Louis, LW Ellisen, DR Borger, AJ Iafrate |
EMBO Molecular Medicine | 2010 |
Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
AS Nagji, SH Cho, Y Liu, JK Lee, DR Jones |
Molecular cancer therapeutics | 2010 |
Guidance molecules in lung cancer.
Nasarre P, Potiron V, Drabkin H, Roche J |
Cell adhesion & migration | 2010 |
Towards patient-based cancer therapeutics
|
Nature Biotechnology | 2010 |
Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK, Bowtell DD |
PloS one | 2010 |
History of leukemia-lymphoma cell lines.
Drexler HG, Macleod RA |
Human Cell | 2010 |
Kinase inhibitors: narrowing down the real targets.
Daub H |
Nature Chemical Biology | 2010 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, S Heynck, I Stückrath, J Weiss, F Fischer, K Michel, A Goel, L Regales, KA Politi, S Perera, M Getlik, LC Heukamp, S Ansén, T Zander, R Beroukhim, H Kashkar, KM Shokat, WR Sellers, D Rauh, C Orr, KP Hoeflich, L Friedman, KK Wong, W Pao, RK Thomas |
Proceedings of the National Academy of Sciences | 2009 |
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, AC Schinzel, P Sandy, E Meylan, C Scholl, S Fröhling, EM Chan, ML Sos, K Michel, C Mermel, SJ Silver, BA Weir, JH Reiling, Q Sheng, PB Gupta, RC Wadlow, H Le, S Hoersch, BS Wittner, S Ramaswamy, DM Livingston, DM Sabatini, M Meyerson, RK Thomas, ES Lander, JP Mesirov, DE Root, DG Gilliland, T Jacks, WC Hahn |
Nature | 2009 |
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)
Y Gong, E Yao, R Shen, A Goel, M Arcila, J Teruya-Feldstein, MF Zakowski, S Frankel, M Peifer, RK Thomas, M Ladanyi, W Pao |
PloS one | 2009 |
Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?
C Benes, J Settleman |
BMC Medicine | 2009 |
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M |
Cancer biology & therapy | 2009 |
Standardized high-throughput evaluation of cell-based compound screens
P Frommolt, RK Thomas |
BMC bioinformatics | 2008 |